Drugs / rVSV HIV envC vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02654080 | Mar 2016 → Aug 2017 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVSV HIV envC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02654080 ↗ |
| Modality | Vaccine | “rVSV HIV envC vaccine” NCT02654080 ↗ |
| Route | Intramuscular | “administered as 1 mL IM in the deltoid” NCT02654080 ↗ |